Similar articles for PMID: 25202102

Year	Number of Results
1975	1
1982	1
1991	2
1993	1
1994	1
1997	1
1998	4
1999	1
2000	1
2001	2
2002	6
2003	1
2004	2
2005	3
2006	7
2007	3
2008	9
2009	13
2010	7
2011	16
2012	20
2013	17
2014	31
2015	28
2016	42
2017	32
2018	15
2019	22
2020	15
2021	17
2022	11
2023	3

1

90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment.

Mondello P, Pitini V, Arrigo C, Derenzini E, Mian M. Mondello P, et al. Anticancer Res. 2014 Sep;34(9):5121-5. Anticancer Res. 2014. PMID: 25202102 Free article.

2

Clinical outcomes of post-remission therapy using (90)yttrium ibritumomab tiuxetan (Zevalin®) for high-risk patients with diffuse large B-cell lymphoma.

Han EJ, Lee SE, Kim SH, Sohn HS, Jung SE, Park G, Choi BO, Lee SN, Yang SW, Han K, Cho SG. Han EJ, et al. Ann Hematol. 2011 Sep;90(9):1075-82. doi: 10.1007/s00277-011-1191-6. Epub 2011 Feb 19. Ann Hematol. 2011. PMID: 21336624 Clinical Trial.

3

90Y-Ibritumomab-Tiuxetan Consolidation Therapy for Advanced-Stage Mantle Cell Lymphoma After First-Line Autologous Stem Cell Transplantation: Is It Time for a Step Forward?

Mondello P, Steiner N, Willenbacher W, Arrigo C, Cuzzocrea S, Pitini V, Mian M. Mondello P, et al. Clin Lymphoma Myeloma Leuk. 2016 Feb;16(2):82-8. doi: 10.1016/j.clml.2015.11.014. Epub 2015 Nov 21. Clin Lymphoma Myeloma Leuk. 2016. PMID: 26702476

4

Upfront consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with stem cell transplantation in poor-risk patients with diffuse large B cell lymphoma.

Fruchart C, Tilly H, Morschhauser F, Ghesquières H, Bouteloup M, Fermé C, Van Den Neste E, Bordessoule D, Bouabdallah R, Delmer A, Casasnovas RO, Ysebaert L, Ciappuccini R, Briere J, Gisselbrecht C. Fruchart C, et al. Biol Blood Marrow Transplant. 2014 Dec;20(12):1905-11. doi: 10.1016/j.bbmt.2014.07.024. Epub 2014 Jul 26. Biol Blood Marrow Transplant. 2014. PMID: 25072780 Free article. Clinical Trial.

5

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.

Hertzberg M, Gandhi MK, Trotman J, Butcher B, Taper J, Johnston A, Gill D, Ho SJ, Cull G, Fay K, Chong G, Grigg A, Lewis ID, Milliken S, Renwick W, Hahn U, Filshie R, Kannourakis G, Watson AM, Warburton P, Wirth A, Seymour JF, Hofman MS, Hicks RJ; Australasian Leukaemia Lymphoma Group (ALLG). Hertzberg M, et al. Haematologica. 2017 Feb;102(2):356-363. doi: 10.3324/haematol.2016.154039. Epub 2016 Nov 10. Haematologica. 2017. PMID: 28143954 Free PMC article. Clinical Trial.

6

Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients.

Zinzani PL, Rossi G, Franceschetti S, Botto B, Di Rocco A, Cabras MG, Petti MC, Stefoni V, Broccoli A, Fanti S, Pellegrini C, Montini GC, Gandolfi L, Derenzini E, Argnani L, Fina M, Tucci A, Bottelli C, Pileri S, Baccarani M. Zinzani PL, et al. Clin Cancer Res. 2010 Aug 1;16(15):3998-4004. doi: 10.1158/1078-0432.CCR-10-0162. Epub 2010 Jun 11. Clin Cancer Res. 2010. PMID: 20542986 Free article. Clinical Trial.

7

Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.

Yoon JH, Kim JW, Jeon YW, Lee SE, Eom KS, Kim YJ, Lee S, Kim HJ, Min CK, Lee JW, Min WS, Park CW, Cho SG. Yoon JH, et al. Korean J Intern Med. 2015 May;30(3):362-71. doi: 10.3904/kjim.2015.30.3.362. Epub 2015 Apr 29. Korean J Intern Med. 2015. PMID: 25995667 Free PMC article.

8

Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results.

Stefoni V, Casadei B, Bottelli C, Gaidano G, Ciochetto C, Cabras MG, Ansuinelli M, Argnani L, Broccoli A, Gandolfi L, Pellegrini C, Zinzani PL. Stefoni V, et al. Blood Cancer J. 2016 May 13;6(5):e425. doi: 10.1038/bcj.2016.29. Blood Cancer J. 2016. PMID: 27176801 Free PMC article.

9

Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group.

Provencio M, Cruz Mora MÁ, Gómez-Codina J, Quero Blanco C, Llanos M, García-Arroyo FR, de la Cruz L, Gumá Padró J, Delgado Pérez JR, Sánchez A, Alvarez Cabellos R, Rueda A; Gotel (Spanish Lymphoma Oncology Group). Provencio M, et al. Leuk Lymphoma. 2014 Jan;55(1):51-5. doi: 10.3109/10428194.2013.790544. Epub 2013 Jun 12. Leuk Lymphoma. 2014. PMID: 23573825 Clinical Trial.

10

A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.

Matsumoto T, Hara T, Shibata Y, Nakamura N, Nakamura H, Ninomiya S, Kitagawa J, Kanemura N, Goto N, Kito Y, Kasahara S, Yamada T, Sawada M, Miyazaki T, Takami T, Takeuchi T, Moriwaki H, Tsurumi H. Matsumoto T, et al. Hematol Oncol. 2017 Sep;35(3):288-295. doi: 10.1002/hon.2285. Epub 2016 Mar 21. Hematol Oncol. 2017. PMID: 26999778

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

281 results

Results by year